Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 1, 2012, Pages 225-232

  Baudy, Andreas R ^a,b   Reeves, Erica K M ^c   Damsker, Jesse M ^c   Heier, Christopher ^b   Garvin, Lindsay M ^a,b   Dillingham, Blythe C ^c   McCall, John ^d   Rayavarapu, Sree ^a,b   Wang, Zuyi ^a,b   Vandermeulen, Jack H ^b   Sali, Arpana ^b   Jahnke, Vanessa ^b   Duguez, Stephanie ^b   DuBois, Debra ^e   Rose, Mary C ^a,b   Nagaraju, Kanneboyina ^a,b   Hoffman, Eric P ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c ReveraGen Biopharma   (United States)

^d PharMac LLC   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; ANECORTAVE DESACETATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MESSENGER RNA; MIFEPRISTONE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ASSAY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DNA STRUCTURE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION PROFILING; GLUCOCORTICOID RESPONSIVE ELEMENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOUSE; MUSCLE FUNCTION; MUSCULAR DYSTROPHY; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SPLEEN SIZE; SWISS JAMES LAMBERT MOUSE; TRANSACTIVATION; TREATMENT DURATION; WEIGHT REDUCTION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MICE, KNOCKOUT; NF-KAPPA B; RESPONSE ELEMENTS; SPLEEN; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 84866327595     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.194340     Document Type: Article

References (40)

1. Almon RR, DuBois DC, Yao Z, Hoffman EP, Ghimbovschi S, and Jusko WJ (2007) Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. Physiol Genomics 30: 282-299. (Pubitemid 47296188)
2. Almon RR, Yang E, Lai W, Androulakis IP, Ghimbovschi S, Hoffman EP, Jusko WJ, and Dubois DC (2008) Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 295:R1031-R1047.
3. Altavilla D, Squadrito F, Campo GM, Squadrito G, Arlotta M, Urna G, Sardella A, Quartarone C, Saitta A, and Caputi AP (1999) The lazaroid, U-74389G, inhibits inducible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock. Eur J Pharmacol 369:49-55. (Pubitemid 29129540)
4. Altavilla D, Squadrito F, Serrano M, Campo GM, Squadrito G, Arlotta M, Urna G, Sardella A, Saitta A, and Caputi AP (1998) Inhibition of tumour necrosis factor and reversal of endotoxin-induced shock by U-83836E, a 'second generation' lazaroid in rats. Br J Pharmacol 124:1293-1299. (Pubitemid 28333955)
5. Bach JR, Martinez D, and Saulat B (2010) Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation. Am J Phys Med Rehabil 89:620-624.
6. Bajenaru ML, Piña Y, Murray TG, Cebulla CM, Feuer W, Jockovich ME, and Marin Castaño ME (2010) Gelatinase expression in retinoblastoma: modulation of LH-(BETA)T(AG) retinal tumor development by anecortave acetate. Invest Ophthalmol Vis Sci 51:2860-2864.
7. Baschant U and Tuckermann J (2010) The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol 120:69-75.
8. Baudy AR, Sali A, Jordan S, Kesari A, Johnston HK, Hoffman EP, and Nagaraju K (2011) Non-invasive optical imaging of muscle pathology in mdx mice using cathepsin caged near-infrared imaging. Mol Imaging Biol 13:462-470.
9. Baudy AR, Saxena N, Gordish H, Hoffman EP, and Nagaraju K (2009) A robust in vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle diseases. Int Immunopharmacol 9:1209-1214.
10. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, et al. (1997) Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277:1597-1604. (Pubitemid 27231191)
11. Burnstein KL, Bellingham DL, Jewell CM, Powell-Oliver FE, and Cidlowski JA (1991) Autoregulation of glucocorticoid receptor gene expression. Steroids 56: 52-58.
12. Campo GM, Squadrito F, Campo S, Altavilla D, Avenoso A, Ferlito M, Squadrito G, and Caputi AP (1997) Antioxidant activity of U-83836E, a second generation lazaroid, during myocardial ischemia/reperfusion injury. Free Radic Res 27: 577-590. (Pubitemid 28051185)
13. Chivers JE, Gong W, King EM, Seybold J, Mak JC, Donnelly LE, Holden NS, and Newton R (2006) Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol 70:2084-2095. (Pubitemid 44771924)
14. Chrousos GA, Kattah JC, Beck RW, and Cleary PA (1993) Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 269: 2110-2112. (Pubitemid 23112630)
15. Clark AF (2007) Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol 52(Suppl 1):S26-S34.
16. De Bosscher K (2010) Selective glucocorticoid receptor modulators. J Steroid Biochem Mol Biol 120:96-104.
17. Di Giovanni S, Molon A, Broccolini A, Melcon G, Mirabella M, Hoffman EP, and Servidei S (2004) Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 55:195-206. (Pubitemid 38166996)
18. Dostert A and Heinzel T (2004) Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des 10:2807-2816. (Pubitemid 39162399)
19. Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, Kornberg AJ, Bertorini TE, Nevo Y, Lotze T, et al. (2011) Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77:444-452.
20. Fukuma K, Marubayashi S, Okada K, Yamada K, Kimura A, and Dohi K (1999) Effect of lazaroid U-74389G and methylprednisolone on endotoxin-induced shock in mice. Surgery 125:421-430. (Pubitemid 29166376)
21. Harris JM, Morgan JE, Rosenblatt JD, Peckham M, Edwards YH, Partridge TA, and Porter AC (1999) Forced MyHCIIB expression following targeted genetic manipulation of conditionally immortalized muscle precursor cells. Exp Cell Res 253: 523-532. (Pubitemid 30003114)
22. Hillier SG (2007) Diamonds are forever: the cortisone legacy. J Endocrinol 195:1-6.
23. Hussein MR, Abu-Dief EE, Kamel NF, and Mostafa MG (2010) Steroid therapy is associated with decreased numbers of dendritic cells and fibroblasts, and increased numbers of satellite cells, in the dystrophic skeletal muscle. J Clin Pathol 63:805-813.
24. Kavanagh RJ and Kam PC (2001) Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth 86:110-119. (Pubitemid 32015592)
25. Morgan JE, Beauchamp JR, Pagel CN, Peckham M, Ataliotis P, Jat PS, Noble MD, Farmer K, and Partridge TA (1994) Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 162:486-498. (Pubitemid 24144125)
26. Newton R and Holden NS (2007) Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 72:799-809. (Pubitemid 47481403)
27. Novac N, Baus D, Dostert A, and Heinzel T (2006) Competition between glucocorticoid receptor and NFkappaB for control of the human FasL promoter. FASEB J 20:1074-1081. (Pubitemid 44943903)
28. Orzechowski A, Ostaszewski P, Wilczak J, Jank M, Ba?asińska B, Wareski P, andFuller J Jr (2002) Rats with a glucocorticoid-induced catabolic state show symptoms of oxidative stress and spleen atrophy: the effects of age and recovery. J Vet Med A Physiol Pathol Clin Med 49:256-263. (Pubitemid 135748530)
29. Passaquin AC, Lhote P, and Rüegg UT (1998) Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br J Pharmacol 124:1751-1759. (Pubitemid 28377109)
30. Puthucheary Z, Harridge S, and Hart N (2010) Skeletal muscle dysfunction in critical care: wasting, weakness, and rehabilitation strategies. Crit Care Med 38:S676-S682.
31. Reed SA, Sandesara PB, Senf SM, and Judge AR (2012) Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J 26:987-1000.
32. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, et al. (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93:531-541. (Pubitemid 28240715)
33. Reichardt HM, Tuckermann JP, Göttlicher M, Vujic M, Weih F, Angel P, Herrlich P, and Schütz G (2001) Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 20:7168-7173. (Pubitemid 34062308)
34. Rhen T and Cidlowski JA (2005) Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353:1711-1723.
35. Schara U, Mortier, and Mortier W (2001) Long-term steroid therapy in Duchenne muscular dystrophy-positive results versus side effects. J Clin Neuromuscul Dis 2:179-183.
36. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, et al. (2009) Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 39:591-602.
37. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, Rayavarapu S, van der Meulen J, Hoffman EP, and Nagaraju K (2011) Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 16:87-95.
38. Taylor BM, Fleming WE, Benjamin CW, Wu Y, Mathews WR, and Sun FF (1996) The mechanism of cytoprotective action of lazaroids I: Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. J Pharmacol Exp Ther 276:1224-1231.
39. Yagi S and Sata M (2011) Pre-clinical data on the role of mineralocorticoid receptor antagonists in reversing vascular inflammation. Eur Heart J Suppl 13 (Suppl B):B15-B20.
40. Yao Z, Hoffman EP, Ghimbovschi S, Dubois DC, Almon RR, and Jusko WJ (2008) Mathematical modeling of corticosteroid pharmacogenomics in rat muscle following acute and chronic methylprednisolone dosing. Mol Pharm 5:328-339. (Pubitemid 351579135)